Background

In the late 1990s, Drs. John M. Boone and Thomas R. Nelson were well-established medical imaging scientists working with breast mammography and computed tomography when an idea hit them. They could marry the two modalities to create an entirely new approach to breast imaging.

Since that time, the U.S. National Institutes of Health and others have invested more than U.S. $19 million to fund development of this groundbreaking breast CT imaging technology. The Isotropic system draws on almost two decades of research and development by inventors Drs. Boone and Nelson, along with many graduate students and senior academic collaborators at the University of California, Davis (UC Davis). Using four increasingly refined prototype systems, Boone and his team have conducted imaging studies on more than 600 patients, including the first studies using a contrast agent to highlight cancerous tissue and other features. The studies clearly demonstrate that the company’s technology is superior to the current standard-of-care mammography for early diagnosis of breast cancer in women.

Birth of Isotropic

In 2016, Izotropic Corporation and its wholly owned U.S. operating subsidiary, Isotropic Imaging Corp. (IIC), were established to begin commercializing this next generation of breast imaging technology. The company secured an exclusive license with UC Davis to commercialize the technology invented by Drs. John M. Boone and Thomas R. Nelson. The license includes all intellectual property, trade secrets, patents, and patent-pending applications that are the foundation of the company’s breast CT Imaging platform.

View the News Release

Current Initiatives

The company is currently developing a fifth system suitable for manufacturing and commercialization. The system, which will be completed in 2018, will be used for regulatory approval, market launch, and commercial sales. In the meantime, Dr. Boone and the team at UC Davis are performing further clinical evaluation of breast CT on 400 women, made possible by a U.S. $2.9 million NIH grant.